

Product datasheet for **TR320311**

CSK Human shRNA Plasmid Kit (Locus ID 1445)

Product data:

| | |
|---------------------------|---|
| Product Type: | shRNA Plasmids |
| Product Name: | CSK Human shRNA Plasmid Kit (Locus ID 1445) |
| Locus ID: | 1445 |
| Vector: | pRS (TR20003) |
| E. coli Selection: | Ampicillin |
| Mammalian Cell Selection: | Puromycin |
| Format: | Retroviral plasmids |
| Components: | CSK - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 1445). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
| RefSeq: | NM_001127190 , NM_004383 , NM_001354988 , NM_004383.1 , NM_004383.2 , NM_001127190.1 , BC106073 , BC106073.1 , BC104847 , BC104875 , NM_001127190.2 |
| UniProt ID: | P41240 |
| Summary: | The protein encoded by this gene is involved in multiple pathways, including the regulation of Src family kinases. It plays an important role in T-cell activation through its association with the protein encoded by the protein tyrosine phosphatase, non-receptor type 22 (PTPN22) gene. This protein also phosphorylates C-terminal tyrosine residues on multiple substrates, including the protein encoded by the SRC proto-oncogene, non-receptor tyrosine kinase gene. Phosphorylation suppresses the kinase activity of the Src family tyrosine kinases. An intronic polymorphism (rs34933034) in this gene has been found to affect B-cell activation and is associated with systemic lupus erythematosus (SLE). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2017] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).